Hamelin Paul 4
4 · SAVIENT PHARMACEUTICALS INC · Filed Feb 19, 2009
Insider Transaction Report
Form 4
Hamelin Paul
President
Transactions
- Sale
Common Stock, $.01 par value per share
2009-12-17$5.77/sh−1,777$10,252→ 97,034 total - Award
Common Stock, $.01 par value per share
2009-12-13$5.94/sh+50,000$297,000→ 98,811 total - Exercise/Conversion
Option to Purchase Common Stock, $.01 par value
2009-02-19$8.27/sh−40,000$330,800→ 140,000 totalExercise: $8.27Exp: 2019-02-19→ Common Stock, $.01 par value per share (40,000 underlying) - Exercise/Conversion
Option to Purchase Common Stock, $.01 par value
2009-02-19$5.27/sh−100,000$527,000→ 100,000 totalExercise: $5.27From: 2010-02-19Exp: 2019-02-19→ Common Stock, $.01 par value per share (100,000 underlying)
Footnotes (3)
- [F1]The right to receive these shares is pursuant to a restricted stock grant and such shares issue and vest as to 33.3% on each of 2/13/10, 2/13/10 and 2/13/11, provided the grantee remains employed by the Company on these dates.
- [F2]These shares were sold automatically pursuant to a binding contract under Rule 10b5-1 of the Securities Exchange Act of 1934, to cover tax withholding obligations in connection with the vesting of restricted stock granted on February 15, 2007.
- [F3]These options will become exercisable as to 25% on each of 2/19/10, 2/19/11, 2/19/12 and 2/19/13, provided the optionee remains employed by the Company on these dates.